Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1)

This study has been completed.
Sponsor:
Collaborators:
Muscular Dystrophy Association
ALS Association
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01041222
First received: December 30, 2009
Last updated: April 12, 2012
Last verified: April 2012